FDA Extends PDUFA Goal Date for Agios' Mitapivat
Agios said the FDA extended its PDUFA goal date for mitapivat, a sickle cell disease treatment. The supplied report does not state the revised date.
Agios said the FDA extended its PDUFA goal date for mitapivat, a sickle cell disease treatment. The supplied report does not state the revised date.